VLST Corporation

company

About

VLST Corporation is developing a novel approach to speed the development of therapeutics to treat inflammatory and autoimmune diseases.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$55M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2004
Number Of Employee
11 - 50
Operating Status
Active

VLST Corporation is a privately held biotechnology company that has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases. The VLST platform uses novel bioinformatics and state-of-the-art proteomics, to identify viral genes whose protein products function as immunomodulatory agents. The resulting product candidates will be either human homologues to these virulence factors or monoclonal antibodies that mimic the function of the virulence gene products. This approach allows for the efficient identification of high quality, pre-validated drug targets for the treatment of autoimmune and inflammatory disorders. The Company's technology has identified potential product candidates for the treatment of disorders such as multiple sclerosis, lupus, psoriasis, rheumatoid arthritis and diabetes.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$55M
VLST Corporation has raised a total of $55M in funding over 2 rounds. Their latest funding was raised on Jun 16, 2006 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 16, 2006 Series B $55M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
VLST Corporation is funded by 2 investors. ARCH Venture Partners and TPG are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series B
TPG Series B